Safety Clinical Trial
Official title:
A Phase 2/3, Randomized, Double-blinded , Parallel Controlled Trial to Evaluate the Immunogenicity, Safety and Efficacy of A Heterologous Booster Dose With COVID-19 mRNA Vaccines (Bivalent) , in Previously Vaccinated Subjects Against COVID-19 With 2/3 Doses COVID-19 Vaccine Compared to a Booster Dose With mRNA COVID-19 Vaccine（Pfizer Bivalent Vaccine）in Adults.
Primary Immunogenicity Objective：Cohort 1: GMTs of SARS-CoV-2 Omicron and related strain neutralizing antibody levels for SWIM816.Cohort 2: To demonstrate the non- inferiority of neutralizing antibody response in terms of geometric mean titers (GMT) of COVID-19 mRNA vaccine(SWIM816) compare with mRNA COVID-19 vaccine(Pfizer Bivalent vaccine) 14 days post dose. Primary Safety Objective：To assess the reactogenicity and safety of a booster dose in a heterologous vaccination regimen in subjects previously immunized with 2/3 doses of COVID-19 vaccine with or without previously diagnosed with COVID-19. Secondary Immunogenicity Objectives：To describe the neutralizing antibody response at D29, D91 and D181.To describe binding antibody profile at D01, D15, D29, D91 and D181 of each study group. Secondary Safety Objective：To assess the reactogenicity and safety of third or fourth booster dose in a heterologous vaccination regimen in subjects previously immunized with 2/3 COVID-19 vaccine doses. Exploratory Objective：1.Documented confirmed SARS-CoV-2 symptomatic infection；2.Todemonstrate the cellular immune response profile at study group (30 subjects per each group for cellular immune testing).
Endpoints: Cohorts 1: GMT of SARS-CoV-2 Omicron (such as BA.5, BQ.1,XBB) and reference strain neutralizing antibody(Delta and other circulating strain) levels for SWIM816 on D15 after study vaccination. Cohorts 1: GMFR of SARS-CoV-2 Omicron (such as BA.5, BQ.1, XBB) and reference strain neutralizing. antibody (other circulating strain) levels for SWIM816 on D15 after study vaccination. Cohorts 1: % of participants with seroresponse to SWIM816 for GMTs of SARS-CoV-2 Omicron(such as BA.5, BQ.1, XBB) and reference strain neutralizing antibody (other circulating strain) levels on D15 after study vaccination. Cohorts 2 (≥18 years ) Non-inferiority analysis: Geometric Mean Ratio (GMR) of SARS-CoV-2 Omicron (such as BA.5, BQ.1,XBB)-neutralizing antibody (other circulating strain) levels for SWIM816 to Pfizer Bivalent vaccine on D15 after study vaccination. Endpoints: Occurrence of local and systemic AEs reported within 7 days after study vaccination. Occurrence of unsolicited AEs reported within 28 days after vaccination. Frequency, severity and relatedness of adverse events within 28 days after vaccination booster dose. Endpoints: Cohorts 1+2 : GMTs of Pseudovirus SARS-CoV-2 Omicron (such as BA.5, BQ.1,XBB) and reference strain neutralizing antibody levels for SWIM816 before and on D29, D91, D181 after study vaccination. Cohorts 1+2 : GMFR of SARS-CoV-2 Omicron (such as BA.5, BQ.1,XBB) and reference strainneutralizingantibody levels for SWIM816 before and on D29, D91, D181 after study vaccination. Cohorts 1: % of participants with seroresponse to SWIM816 for GMTs of SARS-CoV-2 Omicron(such as BA.5, BQ.1, XBB) and reference strain neutralizing antibody (other circulating strain) levels on D29, D91, D181 after study vaccination. Cohorts 1 : GMTs and GMI of IgG profile at D01, D15, D29 , D91and D181 of each study group. Cohorts 1: GMTs of Pseudovirus SARS-CoV-2 Omicron (such as BA.5, BQ.1,XBB) and reference strain neutralizing antibody levels for SWIM516 before and on D15, D29, D91, D181 after study vaccination. Cohorts 1: GMFR of SARS-CoV-2 Omicron (such as BA.5, BQ.1,XBB) and reference strain neutralizing antibody levels for SW-BIC-213 before and on D15, D181 after study vaccination. Endpoints: Serious AEs (SAEs), AEs leading to withdrawal and AEs of special interest (AESIs) within 180 days. Endpoints: Occurrence of confirmed symptomatic cases during the study period. Number of confirmed SARS-CoV-2 symptomatic cases; Severity of confirmed cases of SARS-CoV-2 infection(WHO scale). Number of IFN-γ positive (characterizing Th1) and IL-4 positive (characterizing Th2) T cell subsets on D8 and Day 15 [ Time Frame: Day 8 and Day 15 after the study vaccination .] ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05073744 -
Nalbuphine Versus Morphine for Perioperative Tumor Ablation
|
Phase 4 | |
| Completed |
NCT03969641 -
Safety of RIV4 Versus IIV4 in Pregnant Women
|
Phase 4 | |
| Completed |
NCT05592951 -
Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers
|
N/A | |
| Completed |
NCT04693429 -
Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+
|
Phase 1 | |
| Completed |
NCT01636024 -
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594
|
Phase 1 | |
| Completed |
NCT01415102 -
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.
|
Phase 1 | |
| Completed |
NCT01243502 -
A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT06072170 -
Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience
|
Phase 1 | |
| Completed |
NCT05076253 -
Efficacy of Ivermectin in COVID-19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06060379 -
Giochiamo 626 - Gaming for Health and Safety in Workplaces
|
N/A | |
| Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
| Completed |
NCT05188638 -
Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT05145621 -
Oral Bio-equivalence Study
|
Phase 1 | |
| Recruiting |
NCT05580159 -
New Generation mRNA Booster Vaccine Against Emerging VOCs
|
Phase 3 | |
| Not yet recruiting |
NCT04596956 -
Safety and Efficacy of Sodium Bicarbonate Ringer Injection
|
Phase 4 | |
| Completed |
NCT03033329 -
Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4
|
Phase 1 | |
| Terminated |
NCT01929811 -
NeoMET Study in Neoadjuvant Treatment of Breast Cancer
|
Phase 2 | |
| Completed |
NCT01193335 -
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.
|
Phase 4 | |
| Completed |
NCT03300466 -
A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds
|
N/A | |
| Active, not recruiting |
NCT05686161 -
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
|
Phase 3 |